AstraZeneca closing plant in India; Novartis on track with CAR-T oncology drug;

@FiercePharma: Scientists and ethicists debate 'gene editing' for animal health. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: ICYMI Friday: Sun to launch generic Gleevec Feb. 1 but has said it won't be manufacturing it at troubled Halol plant. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: If Pfizer's consumer health unit goes up for grabs, Reckitt's interested, CEO says. Report | Follow @CarlyHFierce

> Novartis ($NVS) says that with recent study findings, it is on track to submit to the FDA in 2017 what could be the first CAR-T therapy for treating blood cancers. Story

> Germany's Merck KGaA is reconsidering its commitment to its lead cancer candidate after it failed two Phase III studies. Story

> AstraZeneca ($AZN) is closing an API plant in Bengaluru, India. Report

> Biofrontera won approval in Switzerland for Ameluz, its new skin cancer med; the drug is also under review at the FDA. Release (PDF)

Medical Device News

@FierceMedDev: ICYMI Friday: Google Life Sciences edges into Theranos terrain with needle-free, micro blood draw patent filing. Article | Follow @FierceMedDev

@VarunSaxena2: I've never seen a team invent so many ways to lose as the Detroit Lions! I knew it was coming! Unsure of call but it's the Lions after all. | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Cancer drug prices vary across the globe as countries strike deals with Big Pharma: Study. More | Follow @EmilyWFierce

> Danaher tags its industrial unit with the name 'Fortive' as part of the company split. More

> Cepheid nabs FDA OK for point-of-care flu test. Article

Biotech News

@FierceBiotech: Merck KGaA puts a lead cancer drug on the chopping block; Threshold craters. Report | Follow @FierceBiotech

@JohnCFierce: I've got news of a sizable new biotech fund coming up at 6 EST. Stay tuned. | Follow @JohnCFierce

> Kite's CAR-T gets a 'breakthrough' tag with pivotal data on the way. Report

> Biotech startup Laguna Pharma goes bust on a fast PhIII cardio drug flop. Story

> Roche allies with cell engineering startup SQZ on $500M+ immuno-oncology pact. Article

Animal Health News

> Animalytix expands to Canada with acquisition of animal-health data service. Item

> Flu expert warns against USDA move to build bird flu vaccine stockpile. More

> Scientists and ethicists debate 'gene editing' for animal health. Story

> UMass seeks 5,000 dogs for study of genes and brain disorders. Report

> Supreme Court declines to review case on legality of online veterinary services. Article

Biotech IT News

> CDC taps uBiome for large-scale microbiome sequencing initiative. Report

> Genomics England picks Skyscape to provide cloud computing power to sequencing drive. Story

> AstraZeneca wants its scientists to interact on social media. More

> Kite teams with GE in bid to lower T cell production costs through automation. Item

> Venter's HLI adds genome interpretation software in Cypher Genomics buyout. Article

Pharma Marketing News

> Olympic snowboarder Kelly Clark 'vlogs' her acne-med experience for Sun Pharma. More

> AbbVie's Imbruvica, Amgen's Kyprolis shine at annual ASH meeting. Report

> GSK delays Japanese hair-loss treatment launch on Catalent plant problems. Item

> European group joins movement to stop industry cash flows to CME. Story

> With new rivals, Baxalta faces a hemophilia smackdown. So why is Shire bidding? Article

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.